Current state of renal transplant immunosuppression: Present and future

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

710

HTML

7565

Tables (1-6)

201

Sum=8476

Aug 24, 2012 (publication date) through May 10, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Transplantation

ISSN

2220-3230

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Guidelines For Clinical Practice

World J Transplant. Aug 24, 2012; 2(4): 51-68
Published online Aug 24, 2012. doi: 10.5500/wjt.v2.i4.51

Table 3 Non-food and drug administration approved/investigational agents and their mechanism

Name	Mechanism of action
Induction
Alemtuzumab	Monoclonal antibody, CD52
Efaluzimab	Humanized antibody, CD11a/LFA-1
Alefacept	Costimulation inhibitor, CD2 LFA3
Maintenance
Prolonged release tacrolimus	Calcineurin inhibitor
Voclosporin, ISA247	Calcineurin inhibitor
Mizoribine	Purine synthesis inhibitors
Sotrastaurin, AEB071	Protein kinase C inhibitor
Tofacitinib, CP-690550	JAK 3 inhibitor
Treatment of antibody medicated rejection
Bortezomib	Proteasome inhibitor
Eculizumab	Monoclonal antibody, C5 complement protein

Citation: Kalluri HV, Hardinger KL. Current state of renal transplant immunosuppression: Present and future. World J Transplant 2012; 2(4): 51-68
URL: https://www.wjgnet.com/2220-3230/full/v2/i4/51.htm
DOI: https://dx.doi.org/10.5500/wjt.v2.i4.51